Novavax, Inc. (NVAX) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Novavax, Inc. (NVAX) Bundle
Evaluate Novavax, Inc.'s (NVAX) financial outlook like an expert! This (NVAX) DCF Calculator provides pre-populated financial data along with full flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.7 | 475.6 | 1,146.3 | 1,599.0 | 983.7 | 1,478.0 | 2,220.8 | 3,336.8 | 5,013.7 | 7,533.2 |
| Revenue Growth, % | 0 | 2448.48 | 141.02 | 39.49 | -38.48 | 50.25 | 50.25 | 50.25 | 50.25 | 50.25 |
| EBITDA | -114.8 | -398.2 | -1,680.7 | -604.7 | -487.4 | -1,097.0 | -1,648.3 | -2,476.6 | -3,721.1 | -5,591.1 |
| EBITDA, % | -615.31 | -83.73 | -146.63 | -37.82 | -49.55 | -74.22 | -74.22 | -74.22 | -74.22 | -74.22 |
| Depreciation | 5.8 | 4.9 | 12.7 | 29.1 | 41.2 | 115.9 | 174.2 | 261.7 | 393.3 | 590.9 |
| Depreciation, % | 31.08 | 1.03 | 1.1 | 1.82 | 4.19 | 7.84 | 7.84 | 7.84 | 7.84 | 7.84 |
| EBIT | -120.6 | -403.1 | -1,693.4 | -633.8 | -528.6 | -1,117.8 | -1,679.5 | -2,523.5 | -3,791.7 | -5,697.1 |
| EBIT, % | -646.39 | -84.76 | -147.73 | -39.64 | -53.74 | -75.63 | -75.63 | -75.63 | -75.63 | -75.63 |
| Total Cash | 78.8 | 711.0 | 1,515.1 | 1,336.9 | 568.5 | 1,304.8 | 1,960.5 | 2,945.8 | 4,426.1 | 6,650.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 7.5 | 262.0 | 455.0 | 82.4 | 297.2 | 503.5 | 756.6 | 1,136.8 | 1,708.1 | 2,566.4 |
| Account Receivables, % | 40.19 | 55.09 | 39.69 | 5.15 | 30.22 | 34.07 | 34.07 | 34.07 | 34.07 | 34.07 |
| Inventories | -83.0 | -166.7 | -1,957.0 | 36.7 | 41.7 | -675.5 | -1,015.0 | -1,525.0 | -2,291.4 | -3,442.8 |
| Inventories, % | -444.57 | -35.04 | -170.72 | 2.29 | 4.24 | -45.7 | -45.7 | -45.7 | -45.7 | -45.7 |
| Accounts Payable | 2.9 | 54.3 | 127.1 | 216.5 | 132.6 | 192.5 | 289.2 | 434.6 | 653.0 | 981.2 |
| Accounts Payable, % | 15.59 | 11.42 | 11.08 | 13.54 | 13.48 | 13.02 | 13.02 | 13.02 | 13.02 | 13.02 |
| Capital Expenditure | -1.9 | -54.6 | -57.5 | -93.0 | -58.8 | -113.1 | -169.9 | -255.2 | -383.5 | -576.2 |
| Capital Expenditure, % | -9.95 | -11.48 | -5.01 | -5.82 | -5.98 | -7.65 | -7.65 | -7.65 | -7.65 | -7.65 |
| Tax Rate, % | -0.37401 | -0.37401 | -0.37401 | -0.37401 | -0.37401 | -0.37401 | -0.37401 | -0.37401 | -0.37401 | -0.37401 |
| EBITAT | -118.3 | -412.0 | -1,722.3 | -637.9 | -530.6 | -1,113.4 | -1,673.0 | -2,513.7 | -3,776.8 | -5,674.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -36.0 | -581.1 | -97.1 | -2,233.4 | -852.0 | -539.8 | -1,485.5 | -2,232.0 | -3,353.6 | -5,038.9 |
| WACC, % | 12.55 | 12.58 | 12.58 | 12.58 | 12.58 | 12.57 | 12.57 | 12.57 | 12.57 | 12.57 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -8,091.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -5,140 | |||||||||
| Terminal Value | -48,606 | |||||||||
| Present Terminal Value | -26,884 | |||||||||
| Enterprise Value | -34,975 | |||||||||
| Net Debt | -339 | |||||||||
| Equity Value | -34,636 | |||||||||
| Diluted Shares Outstanding, MM | 101 | |||||||||
| Equity Value Per Share | -343.72 |
What You Will Get
- Real NVAX Financial Data: Pre-filled with Novavax’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Novavax’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Model: Features both unlevered and levered DCF valuation frameworks tailored for Novavax, Inc. (NVAX).
- WACC Tool: Pre-configured Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Inputs: Adjust growth projections, capital investments, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency metrics specifically for Novavax.
- Visual Dashboard and Charts: Graphical representations highlight essential valuation indicators for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Novavax, Inc.'s (NVAX) pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions.
Why Choose This Calculator for Novavax, Inc. (NVAX)?
- Designed for Experts: A sophisticated tool utilized by analysts, CFOs, and industry consultants.
- Accurate Data: Novavax's historical and projected financials preloaded for precise calculations.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Instantly computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Clear, step-by-step instructions lead you through the entire process.
Who Should Use This Product?
- Professional Investors: Develop comprehensive valuation models for assessing investment opportunities in Novavax, Inc. (NVAX).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Novavax, Inc. (NVAX) stock.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like Novavax, Inc. (NVAX) are valued in the marketplace.
What the Template Contains
- Preloaded NVAX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.